Finance

Lists
Q2 2027 earnings • released • EPS miss -72.06% • Revenue miss -3.90%
See results
BIOCON:NSE
Biocon Ltd
₹365.10
+0.86%
(+3.10) 1D
Nov 6, 3:30:00 PM GMT+5:30  ·   INR
All symbols
SymbolPriceChange% Change
Generating top insights for BIOCON...
Open
₹360.00
High
₹365.90
Low
₹357.35
Mkt. cap
437.36B
Avg. vol.
3.06M
Volume
5.12M
Dividend
0.14%
Quarterly dividend
₹0.12
Ex-dividend date
Jul 3, 2026
P/E ratio
122.61
52-wk high
₹447.15
52-wk low
₹318.40
EPS
₹2.98
Shares outstanding
600.00M
No. of employees
16K
Open
₹360.00
High
₹365.90
Low
₹357.35
Mkt. cap
437.36B
Avg. vol.
3.06M
Volume
5.12M
Dividend
0.14%
Quarterly dividend
₹0.12
Ex-dividend date
Jul 3, 2026
P/E ratio
122.61
52-wk high
₹447.15
52-wk low
₹318.40
EPS
₹2.98
Shares outstanding
600.00M
No. of employees
16K
News stories
From web sources and news partners
Profile
Biocon Limited is an Indian biopharmaceutical company based in Bengaluru, with U.S. headquarters in Bridgewater, New Jersey. Founded by Kiran Mazumdar-Shaw in 1978 as a partner to the Irish brewing enzyme manufacturer Biocon Biochemicals Ltd., the company manufactures generic active pharmaceutical ingredients that are sold in approximately 120 countries, including the United States and Europe. It also manufactures novel biologics, and branded drugs such as biosimilar insulins and antibodies for the Indian domestic market. Biocon's biosimilar products are also sold in both bulk and formulation forms in several emerging markets. Biocon's formulations for the Indian market include metabolics, oncology, immunotherapy, and nephrology products. Some of Biocon's key brands in India include INSUGEN, BASALOG, BIOMAb EGFR, BLISTO, CANMAb, Evertor, TACROGRAF, ALZUMAb and KRABEVA. Syngene International Limited is a publicly listed subsidiary of Biocon, operating in the contract research and development organization. Wikipedia
About Biocon Ltd
CEOShreehas P Tambe
Employees16.4K
FoundedNov 29, 1978
HeadquartersBengaluru, Karnataka, India
SectorHealth Care
IndustryBiotechnology
Websitebiocon.com
Last report
Nov 4, 2026
Fiscal period
Q2 2027
₹0.29 / ₹1.04
-72.06%miss
Revenue / Est. (INR)
44.23B / 46.03B
-3.90%miss
Fiscal Q2 2027 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in INR
Loading Previous Earnings...
Revenue
Net income
All values in INR
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Revenue
41.73B
45.17B
43.36B
44.23B
Cost of goods sold
13.39B
23.69B
14.68B
15.21B
Cost of revenue
13.39B
23.69B
14.68B
15.21B
Research and development expenses
-531.00M
-128.00M
-16.00M
-445.00M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
8.75B
13.28B
9.16B
8.92B
Operating expense
25.16B
14.45B
25.69B
26.00B
Total operating expenses
38.55B
38.14B
40.36B
41.22B
Operating income
3.18B
7.03B
3.00B
3.02B
Other non operating income
1.17B
-2.52B
545.00M
-
EBT including unusual items
-678.00M
2.48B
1.28B
548.00M
EBT excluding unusual items
2.26B
1.80B
1.41B
615.00M
Income tax expense
-160.00M
489.00M
-92.00M
-19.00M
Effective tax rate
23.60%
19.76%
-7.21%
-3.47%
Other operating expenses
11.78B
-4.12B
11.07B
11.89B
Net income
1.44B
1.26B
1.41B
413.00M
Net profit margin
3.45%
2.79%
3.25%
0.93%
Earnings per share
2.74
1.27
0.95
0.29
Interest and investment income
-
1.15B
-
-
Interest expense
-2.10B
-2.06B
-2.13B
-2.40B
Net interest expenses
-2.10B
-906.00M
-2.13B
-2.40B
Depreciation and amortization charges
5.15B
5.13B
5.47B
5.64B
EBITDA
7.13B
11.62B
7.59B
8.57B
Gain or loss from assets sale
-
-
-
-
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps